<DOC>
	<DOCNO>NCT00663169</DOCNO>
	<brief_summary>This exploratory proof-of-concept study evaluate safety efficacy canakinumab ( ACZ885 ) inflammation pain associate acute gouty arthritis .</brief_summary>
	<brief_title>Efficacy Safety Single Dose Canakinumab ( ACZ885 ) Hospitalized Patients With Acute Gout</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Gouty</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>score 50 0100 VAS pain scale acute , confirm gout flare longer 3 day Treatment biological antitumor necrosis factor ( antiTNF ) within past 3 month Antiinflammatory medication treatment acute gout within previous 24 hour Pregnant breastfeed woman Major surgery high infection risk History severe allergy food drug History risk tuberculosis Active infection Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Arthritis Gouty</keyword>
	<keyword>ACZ885</keyword>
	<keyword>IL1B protein</keyword>
	<keyword>Pain</keyword>
</DOC>